27/06/2022
REX-001 is an autologous multi-cell therapy (MCT) in development for the treatment of chronic limb-threatening ischemia (CLTI) in patients with…
Read More
21/03/2022
London, UK, 21 March 2022– Ixaka Ltd, an integrated cell and gene therapy company, today announces an expansion of its…
Read More
08/03/2022
CELTIC-19 – Ixaka’s targeted nanoparticle for CD19 haematological malignancies – has been granted Advanced Therapy Medicinal Product (ATMP) classification by…
Read More